Welcome to iAluRil.co.uk

Guidance on how to organise home delivery of iAluRil® for your patients.

View the Guidance Document

At Aspire pharma, we acknowledge that for some patients, self-administration might be intimidating. That’s why we’ve put a nurse resource in place, that is on hand to offer support and guidance on the self-administration of iAluRil during this period of clinic cancellation.

Should you wish to recommend this to your patients, all they need do is phone Aspire Pharma on 01730 231148  quoting “self-administration assistance” and their call will be transferred to a Registered Nurse who can help talk them through the procedure.

iAluRil is a medical device presented in a 50ml latex free pre-filled syringe with a Luer-Lock adapter or iAluadapter® for easy use.

IALURIL® Prefill – 50 ml pre-filled syringe is steam sterilized.
IALURIL® Prefill – 50 ml pre-filled syringe is Latex Free.
Luer-Lock Adapter is sterilized using ethylene oxide.1
Ialuadapter® is sterilized using Gamma ray1

iAluRil contains  three active components: 800 mg/50 ml sodium hyaluronate (1.6%), 1 g /50 ml sodium chondroitin sulfate (2%) and calcium chloride (0.87%).

iAluRil can be used for the treatment of:
– Interstitial cystitis/painful bladder syndrome
– Recurrent urinary tract infections
– Chemical-/radiation-induced cystitis (including BCG)

iAluRil® is the first intravesical GAG replacement therapy to combine one of the most abundant sulfated GAG molecules located on the bladder wall,2 chondroitin sulfate, with the most integral component of the GAG layer,3 hyaluronic acid. This combination is designed to facilitate faster and more effective restoration of the bladder epithelium.

GAG Layer Therapy Comparison

Weight of Ingredients per Dose 1214_1010244140-v-1.1-February-2018-iAluRil-GAG-Graph-Comparison_AW-1

Relative Concentrations per ml

iAluRil contains 20-times the concentration of hyaluronic acid compared with the conventional therapy (Cystistat®; Teva UK Ltd.), which contains 0.08% hyaluronic acid, this increase allows for more association sites for a core protein to bind to. Through a link protein the core protein can bind to sulfated glycosaminoglycans such as chondroitin sulfate. Chondroitin sulfate then functions to bind water molecules on the surface of the epithelial lining of the bladder in order to maintain the waterproof and impermeable nature of a healthy bladder.2 Therefore, by increasing the concentration of hyaluronic acid it ultimately increases the number of water molecules bound providing more help in maintaining the healthy state of the bladder.

Available in hospital and community practice. Now available on FP10.


1) iAluRil Prefill Patient Information. 2) Hurst RE et al. Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Surface. J Urol 1987; 138 (2): 433-437. 3) Stryer L. Biochemistry – 4th Edition. W.H. Freeman & Company; 1995. 4. Parsons CL et al. Abnormal Sensitivity to Intravesical Potassium in Interstitial Cystitis and Radiation Cystitis. Neurourol Urodyn 1994; 13(5): 515-520.  5. Damiano R et al. Prevention of Recurrent Urinary Tract Infections by Intravesical Administration of Hyaluronic Acid and Chondroitin Sulfate: a Placebo-Controlled Randomised Trial. Eur Urol 2011; 59(4): 645-651.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
Revision reference – iAluRil_15. 21/04/2022